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Although industrialized countries have been able to
contain recent outbreaks of zoonotic diseases, many
resource-limited and transitioning countries have not been
able to react adequately. The key for controlling zoonoses
such as rabies, echinococcosis, and brucellosis is to focus
on the animal reservoir. In this respect, ministries of health
question whether the public health sector really benefits
from interventions for livestock. Cross-sectoral assess-
ments of interventions such as mass vaccination for brucel-
losis in Mongolia or vaccination of dogs for rabies in Chad
consider human and animal health sectors from a societal
economic perspective. Combining the total societal bene-
fits, the intervention in the animal sector saves money and
provides the economic argument, which opens new
approaches for the control of zoonoses in resource-limited
countries through contributions from multiple sectors.
T
he economic aspects of controlling zoonoses are rapid-
ly gaining attention in light of challenges, both well-
known and new. Wildlife reservoirs of classical and
emerging zoonoses (e.g., bovine tuberculosis) persist in
many countries and substantially slow control efforts for
livestock (1). The fast-growing demand for milk and meat
in urban centers in resource-limited countries is leading to
the intensification of livestock production systems, espe-
cially in periurban areas of these countries. However,
because efficient zoonosis surveillance and food safety are
lacking, the risk for zoonosis transmission is increasing,
particularly in rapidly growing urban centers of resource-
limited countries (2,3). Many countries in postcommunist
transition face a sharp increase in zoonotic diseases result-
ing from the breakdown of government-run disease sur-
veillance and control and weak private health and
veterinary services (4).
Industrialized countries have responded rapidly to
recent zoonosis outbreaks and contained them well (5), but
many resource-limited and transitioning countries have not
been able to respond adequately because they lack human
and financial resources and have not sufficiently adapted
public health surveillance. In industrialized countries, an
important part of successful zoonosis control has been
compensating farmers for culled livestock. However,
many resource-limited countries would not be able to con-
duct such programs.
Most zoonoses are maintained in the animal reservoir
but can cross over to humans as a result of different risk
factors and behavioral traits. For example, brucellosis is
transmitted to humans from direct contact with livestock or
ingestion of unpasteurized milk or milk products; howev-
er, brucellosis is not transmitted from humans to livestock.
Hence, elimination of zoonoses such as rabies, echinococ-
cosis, and brucellosis is possible only by interventions that
vigorously target animal reservoirs. Control of most
zoonoses usually requires interventions outside the public
health sector. When one considers health from a point of
view independent of species, including humans, domestic
animals, and wildlife, zoonoses are part of a broader eco-
logic concept of health systems (6–8). To attempt control,
and possibly elimination, of zoonoses, benefits to public
health and society need to be demonstrated, particularly in
countries with scarce resources. We present examples from
our work on brucellosis and rabies and demonstrate the cir-
cumstances for which zoonosis control would save money
for resource-limited countries and likely reduce the occur-
rence of zoonoses worldwide. Avian influenza is discussed
as an additional example.
Diseases
Brucellosis
In Mongolia and central Asian countries after demo-
cratic reform and the shift from dependence on the former
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Sahel, Bamako, MaliSoviet Union in 1990, human brucellosis reemerged as a
major, but preventable, disease (9). After consultations
with experts, the World Health Organization (WHO) raised
the question whether mass vaccinations of animals saved
money for the public health sector. We used an animal-to-
human transmission model to estimate the economic bene-
fit, cost-effectiveness, and distribution of benefit (to
society and the public health and agricultural sectors) of
mass brucellosis vaccination of cattle and small ruminants
(10). The intervention consisted of a planned 10-year
annual livestock mass vaccination campaign using
Brucella melitensis Rev-1 for small ruminants and
Brucella abortus S19 for cattle. In a scenario of achieving
52% reduction of brucellosis transmission between ani-
mals, 51,856 human brucellosis cases could be averted,
which would add up to a gain of 49,027 human disability-
adjusted life years (DALYs; see Appendix). The human
death rate from brucellosis is considered to be <2% (11)
and was not assessed in this study (4). Estimated interven-
tion costs were US $8.3 million, and the overall benefit
was US $26.6 million (Table 1). This results in a present
net value of $18.3 million and a benefit-to-cost ratio for
society of 3.2 (95% confidence interval [CI] 2.27–4.37). If
the costs of the intervention were shared between the sec-
tors in proportion to the benefit to each, the public health
sector would contribute 11%, with a cost-effectiveness
ratio of $18 per case averted. However this ratio does not
account for illness imposed by brucellosis. When the num-
ber of DALYs averted is assumed to be 49,027, the cost-
effectiveness ratio is $19.1 per DALY averted (95% CI
5.3–486.8). If costs of vaccinating livestock are allocated
proportionally to all benefits, the intervention is cost-sav-
ing and cost-effective for the agricultural and the public
health sectors (4). With such an allocation of costs to ben-
efits per sector, brucellosis control becomes one of the
most cost-effective interventions (<$25 per DALY gained)
in the public health sector, comparable to cost-effective-
ness of vaccinating women and children or treating
tuberculosis.
Rabies
Most human deaths from rabies occur in tropical
resource-limited countries (12). In Africa and Asia, an esti-
mated 24,000–70,000 persons die of rabies each year (13).
The domestic dog is the main source of exposure and vec-
tor for human rabies (14). Rabies in humans can be pre-
vented by appropriate postexposure prophylaxis, which is
not, however, always available and affordable in resource-
limited countries. Human rabies can also be prevented
through vaccination of the animal vector. Again, particu-
larly for countries with limited resources, we must ask
whether it is cost-saving to the public health sector to pre-
vent human rabies by vaccinating dogs. Bögel and Meslin
showed that over 15 years in areas where the virus still cir-
culates in the dog population, dog vaccination combined
with postexposure treatment of dog-bite patients is more
cost-effective than postexposure prophylaxis alone (15).
However, in many countries, little is known about the real
cost of mass vaccination of dogs, and quantitative data are
urgently needed to evaluate the cost-effectiveness of dif-
ferent rabies control strategies in resource-limited coun-
tries; rabies control strategies in developing countries are
currently under review by WHO (F. Meslin, pers. comm.). 
We performed a cost analysis of a pilot dog rabies vac-
cination campaign in which 3,000 dogs in N’Djaména,
Chad, were vaccinated (16). The average cost per dog was
US $2.14 to the public sector (for vaccine and logistics)
and $0.97 to the private-sector dog owner, which brings
the full cost to society to $3.11. If all 23,600 dogs in
N’Djamena were vaccinated, the average cost per dog
would fall to $1.48 for the public sector and $2.45 for soci-
ety (Table 2). Private sector costs account for 31% of the
cost to vaccinate 3,000 dogs and 40% of the cost to vacci-
nate 23,600 dogs (17). The above costs per vaccinated dog
SYNOPSIS
528 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 4, April 2007tally with the estimates by Bögel and Meslin (15). The cost
estimates provided account for only 1 year of vaccination.
In the year before this campaign (16,17), 69 persons were
reported to have been exposed to 29 rabid dogs. If one
assumes that human exposure could be avoided by mass
vaccination of dogs, the cost-effectiveness of mass dog
rabies vaccination would be $837 per averted human expo-
sure ($57,774 per 69 averted exposures). If one assumes
that about 16% of the exposed persons would actually
become ill with rabies and die (18), the cost-effectiveness
would be $57,774 per 11 averted deaths ($5,252 per avert-
ed death). But if we consider that reported human rabies
cases in Africa underestimate the true number of human
rabies cases by a factor of 10 to 100 (18), then the cost-
effectiveness would be $52–$525 per averted death.
Hence, mass vaccination of dogs is a comparatively inex-
pensive and ethical way to control the disease in animals
and to prevent human exposure and illness, especially in
resource-limited countries. More research is needed to
assess the dynamics of dog-to-human rabies transmission
and the frequency of revaccination programs needed
because of turnover in dog populations and continued risk
for reintroduction of rabies from outside sources to unvac-
cinated dogs.
Avian Influenza
The spread of highly pathogenic avian influenza is a
global threat to all countries that have a poultry industry,
semicommercial poultry production, or backyard poultry
operations and has already caused enormous economic
losses (19). Moreover, the risk for human pandemic
influenza originating from highly pathogenic avian
influenza in conjunction with human influenza A virus is
very high, with an estimate of >100,000 deaths for the
United States alone (20). To implement disease prevention
and control measures, early identification of emerging pat-
terns of disease is necessary and uses economic methods to
determine which mix of measures is most cost-effective.
Resource-limited countries in Africa are almost devoid of
surveillance capacity and efficient early warning systems,
which would be crucial. Surveillance of cross-border dis-
eases cannot be restricted to countries that have the funds.
High-income countries would ultimately benefit by pro-
viding funding for surveillance and control to low-income
countries. Comprehensive economic assessment of this
issue are, however, lacking so far.
Awareness, Knowledge, and Information
Many countries, especially those with resource con-
straints and those in sub-Saharan Africa, lack information
on the distribution of zoonotic diseases. Risks for zoonoses
are considered negligible compared with those for diseases
of higher consequence because the societal consequences
of zoonoses are not recognized by the individual sectors.
For example, outbreaks of Rift Valley fever in persons in
Mauritania were mistakenly identified as yellow fever. The
correct diagnosis was made only after public health servic-
es contacted livestock services, which informed them of
abortions in cattle (21). In resource-limited and transition-
ing countries, many zoonoses are not controlled effective-
ly because adequate policies and funding are lacking.
However, transmission of zoonoses to humans can already
be greatly reduced by health information and behavior.
Authorities in Kyrgyzstan, for example, have started an
information campaign to reduce brucellosis transmission
to small-ruminant herders by encouraging them to wear
gloves for lambing and to boil milk before consuming.
Interventions in livestock should always be accompanied
by mass information, education, and communication
programs.
Financing
Substantial evidence documents that the combined
effects of human disease caused by zoonoses, as part of the
neglected infectious diseases, are in the same range as the
classical diseases of poverty such as HIV/AIDS, tubercu-
losis, and malaria (22,23). On the other hand, the public
health component justifies including zoonoses such as
bovine tuberculoses in current global programs and initia-
tives on tuberculosis control (22,23). Recognition of these
facts should result in affected countries applying for funds
from the Global Fund to Fight AIDS, Tuberculosis and
Malaria (24). Surveillance and control of cross-border
zoonotic diseases such as highly pathogenic avian influen-
za cannot be restricted to wealthy countries. According to
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and rapid response to animal disease outbreaks can repre-
sent a threat to all the others” (25). To approach these
threats, new partnerships (e.g., between resource-limited
and industrial countries, public and private sectors, and
animal and public health) and permanent dialogue are
needed. “It is evident that the interest of the rich countries
is to support the others in order to protect themselves”
(25). Zoonosis control in general should thus be seen from
a global perspective and lead to a call for a global sub-
sidiary approach for control. International bodies like the
World Organization for Animal Health, the Food and
Agriculture Organization, and WHO should foster estab-
lishment of global standards for zoonosis surveillance and
control. Fostering of global standards is also part of the
WHO International Health Regulations that will come into
force in mid-2007 and will require all countries to do a bet-
ter job of surveillance for diseases that can spread between
countries (www.who.int/gb/edwha/pdf_files/WHA58-
REC1/english/Resolutions.pdf). These efforts should lead
to a global fund for the control of zoonoses or become a
component of an extended Global Fund to Fight AIDS,
Tuberculosis and Malaria. Such a joint facility would
allow coherent and integrated control approaches, particu-
larly in the countries with the most serious resources con-
straints, which in turn would benefit the whole world.
Conclusion
Zoonoses are among the most important animal and
public health problems that affect the well-being of soci-
eties worldwide, yet they are too often forgotten or neg-
lected. Because most zoonoses go unrecorded, they call for
a rethinking of research and control efforts and the eco-
nomic consequences. The example of brucellosis demon-
strates that interventions in livestock against zoonoses,
which would never be cost-effective when uniquely
assessed from a public health sector point of view, may
become cost-saving when considered from a societal per-
spective. Creating a new global finance facility for the
control of zoonoses, similar to or linked with the Global
Fund to Fight AIDS, Tuberculosis and Malaria, is timely,
is of global interest, and represents a further contribution
to successful attainment of the Millennium Development
Goals.
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Appendix. Estimating Disability-adjusted Life Years 
Disability-adjusted life years (DALYs) are used in the glob-
al comparative assessments of the burden of disease (26) and
enable costs of interventions to be related to a standardized health
outcome across diseases internationally. DALYs is an indicator of
the time lived with a disability and the time lost because of pre-
mature death (Formula 1).
DALYs = years of life lost + years of life with a disability      (1)
The duration of time lost due to premature death is calculat-
ed by using standard expected years of life lost with model life
tables. The reduction in physical capacity due to illness is meas-
ured by using disability weights. To calculate the reduction in
physical capacity, the following formula is used (Formula 2)
(26):
where a is the age at onset of disease, L is the duration of disabil-
ity or time lost due to premature mortality, D is the disability
weight (or 1 for premature mortality), r is the discount rate, C is
the age-weighting correction constant, and β is the parameter
from the age-weighting function. 
An estimate of the burden of disease for brucellosis is not
readily available, so we therefore estimated the DALYs as a
result of the disease by assuming that brucellosis is associated
with a class II (0.2) disability weight (D), as the disease is per-
ceived as very painful and affects occupational ability even dur-
ing periods of remission (27). Average age at onset was
calculated for every age group. For the duration of illness, we
considered data by Beklemishev on the duration of clinical cure
of 1,000 patients with brucellosis in the Russian Federation (28).
The frequency distribution of clinical disease duration fits best
with an exponential function for an average duration of 4.5 years.
For duration of disease, we used @Risk (Palisade Corporation,
Newfield, NY, USA) exponential function; β = 4.5 years. For
cost-effectiveness, we used the median of the cumulated dis-
counted DALYs, which corresponds to a median duration (L) of
brucellosis of 3.11 years (4).
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